Finch therapeutics update#
Finch therapeutics trial#

These forward-looking statements include, but are not limited to, statements regarding: the financial and strategic impact of the termination of Finch’s collaboration with Takeda the potential for opportunities to leverage third-party clinical data to inform Finch’s autism program Finch’s strategic review and plans with respect to its business and portfolio, including the initiation of future clinical trials Finch’s anticipated runway and Finch’s ability to develop a novel class of orally administered biological drugs. This press release includes “forward-looking statements.” Words such as “will,” 'anticipates,' 'believes,' 'expects,' 'intends,' “plans,” “potential,” 'projects,” “would” and 'future' or similar expressions are intended to identify forward-looking statements. Human-First Discovery® is a registered trademark of Finch Therapeutics Group, Inc. Finch encourages investors to consult the “Investors & News” section of its website regularly. Finch routinely posts information that may be important to its investors on its website at. Finch’s pipeline also includes FIN-211 for children with autism spectrum disorder and significant gastrointestinal symptoms, FIN-524 for the treatment of ulcerative colitis, and FIN-525 for the treatment of Crohn’s disease.

difficile infection and has received Breakthrough Therapy and Fast Track designations from the U.S. Finch’s lead candidate, CP101, is in late-stage clinical development for the prevention of recurrent C. With the capabilities to develop both complete and targeted microbiome therapeutics, Finch has a rich pipeline of candidates designed to address a wide range of unmet medical needs. About Finch Therapeuticsįinch Therapeutics is a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs. The Company will provide further updates on the strategy for each of its product candidates and its cash runway in the future. Smith continued, “I’d like to extend my sincere gratitude to our departing colleagues for their dedication to our mission and their tremendous contributions that have helped us pioneer this new modality and bring hope to many patients and families in need.”

Finch therapeutics trial#

“As part of this ongoing review, we have decided to suspend efforts to initiate the Phase 1 trial of our IND-ready candidate FIN-211 while we explore opportunities to leverage clinical data from ongoing third-party studies to inform our autism program strategy going forward.”ĭr.

“Following the recent discontinuation of our IBD collaboration with Takeda, coupled with the current capital market environment, we are evaluating our strategy across our entire portfolio and have made the difficult decision to reduce our workforce,” said Mark Smith, PhD, Chief Executive Officer of Finch Therapeutics. This decision follows Finch’s recent announcement that it is assessing the financial and strategic impact of Takeda’s decision to discontinue its inflammatory bowel disease (IBD) collaboration with Finch. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, today announced plans to reduce its workforce by approximately 37% as part of an ongoing strategic review of its business and portfolio. 01, 2022 (GLOBE NEWSWIRE) - Finch Therapeutics Group, Inc.

Finch therapeutics update#

Finch Therapeutics Provides Business Update